{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Basu S"],"funding":["NIDDK NIH HHS","NHLBI NIH HHS","NIMHD NIH HHS"],"pagination":["788-798"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5769867"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(10)"],"pubmed_abstract":["Background
In view of substantial mis-estimation of risks of diabetes complications using existing equations, we sought to develop updated Risk Equations for Complications Of type 2 Diabetes (RECODe).Methods
To develop and validate these risk equations, we used data from the Action to Control Cardiovascular Risk in Diabetes study (ACCORD, n=9635; 2001-09) and validated the equations for microvascular events using data from the Diabetes Prevention Program Outcomes Study (DPPOS, n=1018; 1996-2001), and for cardiovascular events using data from the Action for Health in Diabetes (Look AHEAD, n=4760; 2001-12). Microvascular outcomes were nephropathy, retinopathy, and neuropathy. Cardiovascular outcomes were myocardial infarction, stroke, congestive heart failure, and cardiovascu"],"journal":["The lancet. Diabetes & endocrinology"],"pubmed_title":["Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials."],"pmcid":["PMC5769867"],"funding_grant_id":["P30 DK092926","DP2 MD010478","K23 DK109200","P60 DK020572","L30 DK103291","R01 HL132814","K08 HL121056","U54 MD010724"],"pubmed_authors":["Yudkin JS","Sussman JB","Berkowitz SA","Hayward RA","Basu S"],"additional_accession":[]},"is_claimable":false,"name":"Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials.","description":"Background
In view of substantial mis-estimation of risks of diabetes complications using existing equations, we sought to develop updated Risk Equations for Complications Of type 2 Diabetes (RECODe).Methods
To develop and validate these risk equations, we used data from the Action to Control Cardiovascular Risk in Diabetes study (ACCORD, n=9635; 2001-09) and validated the equations for microvascular events using data from the Diabetes Prevention Program Outcomes Study (DPPOS, n=1018; 1996-2001), and for cardiovascular events using data from the Action for Health in Diabetes (Look AHEAD, n=4760; 2001-12). Microvascular outcomes were nephropathy, retinopathy, and neuropathy. Cardiovascular outcomes were myocardial infarction, stroke, congestive heart failure, and cardiovascu","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Oct","modification":"2025-04-27T04:18:14.952Z","creation":"2019-03-27T00:15:04Z"},"accession":"S-EPMC5769867","cross_references":{"pubmed":["28803840"],"doi":["10.1016/s2213-8587(17)30221-8","10.1016/S2213-8587(17)30221-8"]}}